US2023201254A1PendingUtilityA1

Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits

71
Assignee: UNIV YALEPriority: Apr 27, 2011Filed: Dec 2, 2022Published: Jun 29, 2023
Est. expiryApr 27, 2031(~4.7 yrs left)· nominal 20-yr term from priority
Inventors:Barbara EhrlichSara RockwellJennifer Benbow
A61K 31/20A61K 31/5415A61K 31/19A61K 38/57A61K 45/06A61K 31/416A61K 31/337A61K 33/00A61K 33/14G01N 33/5044A61K 31/437A61P 35/00A61P 43/00
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.

Claims

exact text as granted — not AI-modified
1 - 61 . (canceled) 
     
     
         62 . A method of treating peripheral neuropathy in a subject undergoing anticancer treatment with paclitaxel, the method comprising co-administering to the subject an effective amount of lithium. 
     
     
         63 . The method of  claim 62 , wherein paclitaxel is the only taxane anticancer treatment being administered to the subject. 
     
     
         64 . The method of  claim 62 , wherein said lithium is lithium chloride. 
     
     
         65 . The method of  claim 63 , wherein said lithium is lithium chloride. 
     
     
         66 . The method of  claim 62 , wherein said treating comprises inhibiting and/or reducing the likelihood of peripheral neuropathy. 
     
     
         67 . The method of  claim 63 , wherein said treating comprises inhibiting and/or reducing the likelihood of peripheral neuropathy. 
     
     
         68 . The method of  claim 65 , wherein said treating comprises inhibiting and/or reducing the likelihood of peripheral neuropathy. 
     
     
         69 . The method of  claim 62 , wherein said treating comprises inhibiting peripheral neuropathy. 
     
     
         70 . The method of  claim 63 , wherein said treating comprises inhibiting peripheral neuropathy. 
     
     
         71 . The method of  claim 65 , wherein said treating comprises inhibiting peripheral neuropathy. 
     
     
         72 . The method of  claim 62 , wherein said treating comprises reducing the likelihood peripheral neuropathy. 
     
     
         73 . The method of  claim 63 , wherein said treating comprises reducing the likelihood peripheral neuropathy. 
     
     
         74 . The method of  claim 65 , wherein said treating comprises reducing the likelihood peripheral neuropathy. 
     
     
         75 . A method of treating peripheral neuropathy in a subject who is suffering from lung cancer, breast cancer, ovarian cancer, or prostate cancer and who is undergoing anticancer treatment with paclitaxel, the method comprising co-administering to the subject an effective amount of lithium. 
     
     
         76 . The method of  claim 75 , wherein the subject is suffering from breast cancer. 
     
     
         77 . The method of  claim 75 , wherein said lithium is lithium chloride. 
     
     
         78 . The method of  claim 76 , wherein said lithium is lithium chloride. 
     
     
         79 . The method of  claim 75 , wherein said treating comprises inhibiting and/or reducing the likelihood of peripheral neuropathy. 
     
     
         80 . The method of  claim 76 , wherein said treating comprises inhibiting and/or reducing the likelihood of peripheral neuropathy. 
     
     
         81 . The method of  claim 78 , wherein said treating comprises inhibiting and/or reducing the likelihood of peripheral neuropathy. 
     
     
         82 . The method of  claim 75 , wherein said treating comprises inhibiting peripheral neuropathy. 
     
     
         83 . The method of  claim 76 , wherein said treating comprises inhibiting peripheral neuropathy. 
     
     
         84 . The method of  claim 78 , wherein said treating comprises inhibiting peripheral neuropathy. 
     
     
         85 . The method of  claim 75 , wherein said treating comprises reducing the likelihood peripheral neuropathy. 
     
     
         86 . The method of  claim 76 , wherein said treating comprises reducing the likelihood peripheral neuropathy. 
     
     
         87 . The method of  claim 78 , wherein said treating comprises reducing the likelihood peripheral neuropathy.

Join the waitlist — get patent alerts

Track US2023201254A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.